GlaxoSmithKline Inc

Registered Principal Details

Business Or Interest:
Pharmaceutical Manufacturer.

Lobbying Interests:
Lobby areas of healthcare, wellness, and pharmaceutical issues.

CEO Name:
Andrew Witty
Director, State Government Affairs

Contact
SB
Sandie Benen
47 W. Division Street, #234
Chicago, IL 60610
(312) 504-4080
(312) 335-9821
sandra.e.benen@gsk.com
http://www.gsk.com

Authorized Lobbyists

Lobbyist Name Exclusive Duties Authorized On Withdrawn On
Sandie Benen Exclusive Duties N/A Authorized On 1/21/2011 Withdrawn On N/A
Peter Kammer Exclusive Duties N/A Authorized On 2/23/2011 Withdrawn On N/A
Heather Berlinski Exclusive Duties N/A Authorized On 2/23/2011 Withdrawn On N/A

Lobbying Interests

Legislative Bills/Resolutions

Assembly Bill 151
Assembly Bill 151
Relating to: copayments, deductibles, or coinsurance for oral chemotherapy and injected or intravenous chemotherapy.

Bill Text and History

For
Notification Date
6/3/2011
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Senate Bill 101
Senate Bill 101
Relating to: copayments, deductibles, or coinsurance for oral chemotherapy and injected or intravenous chemotherapy.

Bill Text and History

For
Notification Date
6/3/2011
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Senate Bill 373
Senate Bill 373
Relating to: changes to product liability law and the law governing remedies against manufacturers, distributors, sellers, and promoters of a product.

Bill Text and History

None
Notification Date
1/12/2012
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
September 2011 Special Session Assembly Bill 13
September 2011 Special Session Assembly Bill 13
Relating to: providing immunity from liability to drug and device manufacturers and sellers under certain circumstances.

Bill Text and History

For
Notification Date
10/21/2011
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Budget Bill Subjects

Health Services: Medical Assistance and Related Programs
Biennial budget bill treatment of matter relating to
Health Services: Medical Assistance and Related Programs

Notification Date
5/18/2011
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Comments
Medicaid reimbursement

Notification Date
5/18/2011
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Comments
Drug substitution

Topics Not Yet Assigned A Bill Or Rule Number

Health care reform including health insurance exchanges
Development, drafting or introduction of a proposal relating to
Health care reform including health insurance exchanges

Action Intended To Affect
Legislative matter

Notification Date
7/26/2012
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.

Health care reform including health insurance exchanges.
Development, drafting or introduction of a proposal relating to
Health care reform including health insurance exchanges.

Action Intended To Affect
Legislative Matter

Notification Date
7/26/2012
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Transparency in private attorney contracting
Development, drafting or introduction of a proposal relating to
Transparency in private attorney contracting

Action Intended To Affect
Legislative Matter

Notification Date
5/18/2011
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Transparency in private attorney action.
Development, drafting or introduction of a proposal relating to
Transparency in private attorney action.

Action Intended To Affect
Legislative Matter

Notification Date
3/5/2011
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Relating to the out of pocket cost for orally administered anitcancer medication.
Development, drafting or introduction of a proposal relating to
Relating to the out of pocket cost for orally administered anitcancer medication.

Action Intended To Affect
Legislative Matter

Notification Date
1/1/2011
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Restrictions on material provided to physicians by pharmaceutical and healthcare product manufacturers.
Development, drafting or introduction of a proposal relating to
Restrictions on material provided to physicians by pharmaceutical and healthcare product manufacturers.

Action Intended To Affect
Both Legislative Matter and Rule

Notification Date
1/1/2011
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Total Lobbying Effort

  2011
January - June
2011
July - December
2012
January - June
2012
July - December
Total
Total Lobbying Expenditures 2011
January - June
$15,792.00
2011
July - December
$23,448.75
2012
January - June
$18,836.25
2012
July - December
$11,216.00
Total $69,293.00
Total Hours Communicating 2011
January - June
20.75
2011
July - December
56.25
2012
January - June
21.25
2012
July - December
8.75
Total 107.00
Total Hours Other 2011
January - June
61.50
2011
July - December
113.40
2012
January - June
70.50
2012
July - December
42.50
Total 287.90

Percent Allocation of Lobbying Effort

Legislative Bills/Resolutions

Relating to: copayments, deductibles, or coinsurance for oral chemotherapy and injected or intravenous chemotherapy.
2011
January - June
2011
July - December
2012
January - June
2012
July - December
Total
2011
January - June
20%
2011
July - December
45%
2012
January - June
60%
2012
July - December
Total 37%
Relating to: copayments, deductibles, or coinsurance for oral chemotherapy and injected or intravenous chemotherapy.
2011
January - June
2011
July - December
2012
January - June
2012
July - December
Total
2011
January - June
40%
2011
July - December
30%
2012
January - June
20%
2012
July - December
Total 26%
Relating to: changes to product liability law and the law governing remedies against manufacturers, distributors, sellers, and promoters of a product.
2011
January - June
2011
July - December
2012
January - June
2012
July - December
Total
2011
January - June
2011
July - December
5%
2012
January - June
2012
July - December
Total 2%
Relating to: providing immunity from liability to drug and device manufacturers and sellers under certain circumstances.
2011
January - June
2011
July - December
2012
January - June
2012
July - December
Total
2011
January - June
2011
July - December
10%
2012
January - June
2012
July - December
Total 4%

Budget Bill Subjects

2011
January - June
2011
July - December
2012
January - June
2012
July - December
Total
2011
January - June
10%
2011
July - December
2012
January - June
2012
July - December
Total 2%

Administrative Rulemaking Proceedings

No administrative rulemaking proceedings found.

Topics Not Yet Assigned A Bill Or Rule Number

2011
January - June
2011
July - December
2012
January - June
2012
July - December
Total
2011
January - June
15%
2011
July - December
2012
January - June
2012
July - December
Total 3%
2011
January - June
2011
July - December
2012
January - June
2012
July - December
Total
2011
January - June
15%
2011
July - December
2012
January - June
2012
July - December
Total 3%
2011
January - June
2011
July - December
2012
January - June
2012
July - December
Total
2011
January - June
2011
July - December
2012
January - June
10%
2012
July - December
80%
Total 13%
2011
January - June
2011
July - December
2012
January - June
2012
July - December
Total
2011
January - June
2011
July - December
2012
January - June
2012
July - December
10%
Total 1%

Minor Efforts

(Time spent on matters each of which accounted for less than 10% of the organization's lobbying.)

Minor Efforts
2011
January - June
2011
July - December
2012
January - June
2012
July - December
Total
2011
January - June
2011
July - December
10%
2012
January - June
10%
2012
July - December
10%
Total 8%

Other Matters

No other matters found.

Filed Statements of Lobbying Activity and Expenditures